A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations

TAS0728 is an oral covalent binding inhibitor of human epidermal growth factor receptor 2 (HER2). A first-in-human open-label, dose-escalation, phase I study (NCT03410927) was initiated to investigate the safety and dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) and/o...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Piha-Paul, Sarina A., Azaro, Analía, Arkenau, Hendrik Tobias, Oh, Do-Youn, Galsky, Matthew D., Pal, Sumanta Kumar, Hamada, Kensuke, He, Yaohua, Yamamiya, Ikuo, Benhadji, Karim A, Hollebecque, Antoine
التنسيق: Online مقال نص
اللغة:English
منشور في: Springer US 2021
الموضوعات:
Phase I Studies
الوصول للمادة أونلاين:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426237/
https://www.ncbi.nlm.nih.gov/pubmed/33774767
http://dx.doi.org/10.1007/s10637-021-01104-7

الانترنت

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426237/
https://www.ncbi.nlm.nih.gov/pubmed/33774767
http://dx.doi.org/10.1007/s10637-021-01104-7

مواد مشابهة